Significant Progress in Duchenne Muscular Dystrophy Treatment: Brogidirsen's 4.5-Year Clinical Data Unveiled NS Pharma's presentation at the 2026 MDA Conference reveals impressive 4.5-year clinical trial results for Brogidirsen in treating DMD, showcasing long-term efficacy and safety.

Significant Progress in Duchenne Muscular Dystrophy Treatment: Brogidirsen's 4.5-Year Clinical Data Unveiled #USA #NS_Pharma #Paramus #Duchenne_Muscular_Dystrophy #Brogidirsen

Brogidirsen Clinical Trial Results Offer Hope for DMD Treatment at 2025 World Muscle Society Congress NS Pharma presented promising 3.5-year clinical trial data for brogidirsen as a treatment for Duchenne muscular dystrophy at the 2025 World Muscle Society Congress.

Brogidirsen Clinical Trial Results Offer Hope for DMD Treatment at 2025 World Muscle Society Congress #None #NS_Pharma #Paramus #Duchenne_Muscular_Dystrophy #Brogidirsen

Brogidirsen (NS-089/NCNP-02) has The Potential to Slow Disease Progression in DMD Patients Amenable to Exon 44 Skipping Nippon Shinyaku announced efficacy and safety data from a 3.5-year application based on an open-label extension study that also included the initiation of a clinical trial for brogidirsen (NS-089/NCNP-02). #dmd #duchenne #exon44 #brogidirsen 👉 Read More: DMDWarrioR.com

Brogidirsen (NS-089/NCNP-02) has The Potential to Slow Disease Progression in DMD Patients Amenable to Exon 44 Skipping

#dmd #duchenne #exon44 #brogidirsen

👉 Read More: DMDWarrioR.com

Nippon Shinyaku Releases First Clinical Trial (First in Human) of Brogidirsen NS-089/NCNP-02 for the Treatment of Duchenne Nippon Shinyaku Corporation has announced the first human trial results of its drug 'Brogidirsen' (NS-089/NCNP-02), which was developed for exon 44 skipping in the treatment of Duchenne muscular dystrophy (DMD). The National Center of Neurology and Psychiatry is announced the publication of a research paper in Cell Reports Medicine detailing the results of an investigator-initiated trial for NS-089/NCNP-02, known as “brogidirsen.” This innovative treatment for Duchenne muscular dystrophy (DMD), jointly developed with Nippon Shinyaku Co., Ltd., represents a significant advancement in exon 44 skipping therapy. What is Brogidirsen? Brogidirsen (NS-089/NCNP-02) is a nucleic acid drug co-discovered by Nippon Shinyaku and NCNP, and is expected to be a therapeutic drug for DMD patients with dystrophin gene mutations amenable to exon 44 skipping.

Nippon Shinyaku Releases First Clinical Trial (First in Human) of Brogidirsen NS-089/NCNP-02 for the Treatment of Duchenne

What is Brogidirsen?

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #nipponshinyaku #brogidirsen #NS089 #exonskipping #exon44